Your search returned 6 results.

Results
	1.	Urodynamics and safety of the β₃-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. [electronic resource] by Nitti, Victor W Rosenberg, Steven Mitcheson, David H He, Weizhong Fakhoury, Allam Martin, Nancy E Producer: 20131211 In: The Journal of urology vol. 190 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year. [electronic resource] by Chapple, Christopher R Kaplan, Steven A Mitcheson, David Blauwet, Mary Beth Huang, Moses Siddiqui, Emad Khullar, Vik Producer: 20150701 In: International journal of urology : official journal of the Japanese Urological Association vol. 21 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. [electronic resource] by Chapple, Christopher R Kaplan, Steven A Mitcheson, David Klecka, Jiri Cummings, Jana Drogendijk, Ted Dorrepaal, Caroline Martin, Nancy Producer: 20130708 In: European urology vol. 63 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	4.	Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE). [electronic resource] by Drake, Marcus J MacDiarmid, Scott Chapple, Christopher R Esen, Adil Athanasiou, Stavros Cambronero Santos, Javier Mitcheson, David Herschorn, Sender Siddiqui, Emad Huang, Moses Stoelzel, Matthias Producer: 20180716 In: International journal of clinical practice vol. 71 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	5.	Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). [electronic resource] by Herschorn, Sender Chapple, Christopher R Abrams, Paul Arlandis, Salvador Mitcheson, David Lee, Kyu-Sung Ridder, Arwin Stoelzel, Matthias Paireddy, Asha van Maanen, Rob Robinson, Dudley Producer: 20171213 In: BJU international vol. 120 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	6.	Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). [electronic resource] by Drake, Marcus J Chapple, Christopher Esen, Ahmet A Athanasiou, Stavros Cambronero, Javier Mitcheson, David Herschorn, Sender Saleem, Tahir Huang, Moses Siddiqui, Emad Stölzel, Matthias Herholdt, Claire MacDiarmid, Scott Producer: 20171221 In: European urology vol. 70 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)